Verrica Pharmaceuticals Announces Launch of YCANTH® for the Treatment of Molluscum Contagiosum in Japan by Partner Torii Pharmaceutical

Detailed price information for Verrica Pharmaceuticals Inc (VRCA-Q) from The Globe and Mail including charting and trades.
BioWorld

Other news to note for Feb. 11, 2026

Biopharma and med-tech happenings, including deals and partnerships, and other news in brief: Arthrosi, Avia Vascular, Calla Lily, Cortec, Cumulus, Dynavax, Foghorn, Generation Bio, Merck, Sanofi, ...

Cumulus Neuroscience Enters Japanese Market to Advance Novel Cognitive Biomarkers with New Customer Shionogi & Co., Ltd.

Cumulus Neuroscience (Cumulus; The Company), a global digital health company focused on advancing neuroscience clinical ...
Le Lézard

Invasive Fungal Infections Market to Witness Upsurge in Growth at a CAGR of 11.4% (in the US) During the Forecast Period (2025-2034) | DelveInsight

DelveInsight's Invasive Fungal Infections Market Insights report includes a comprehensive understanding of current treatment ...

DelveInsight Business Research, LLP: Invasive Fungal Infections Market to Witness Upsurge in Growth at a CAGR of 11.4% (in the US) During the Forecast Period (2025-2034 ...

The invasive fungal infections market is expected to grow by 2034, owing to the approval of new agents such as Ibrexafungerp (Glaxosmithkline/SCYNEXIS), Fosmanogepix (Basilea Pharmaceutica) ...
Investing.com Australia

Verrica Pharmaceuticals stock rises after partner launches YCANTH in Japan

Investing.com -- Verrica Pharmaceuticals Inc (NASDAQ:VRCA) stock rose 3.1% on Monday after the company announced that its partner, Torii Pharmaceutical, has launched YCANTH in Japan for the treatment ...

Verrica Pharmaceuticals Inc.: Verrica Pharmaceuticals Announces Launch of YCANTH for the Treatment of Molluscum Contagiosum in Japan by Partner Torii Pharmaceutical

Verrica Pharmaceuticals Inc. ("Verrica") (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring ...